1. Home
  2. CANF vs PT Comparison

CANF vs PT Comparison

Compare CANF & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

N/A

Current Price

$0.27

Market Cap

4.8M

Sector

Health Care

ML Signal

N/A

Logo Pintec Technology Holdings Limited

PT

Pintec Technology Holdings Limited

N/A

Current Price

$0.98

Market Cap

14.7M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CANF
PT
Founded
1994
2012
Country
Israel
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
14.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CANF
PT
Price
$0.27
$0.98
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$3.25
N/A
AVG Volume (30 Days)
19.8M
53.3K
Earning Date
02-03-2026
09-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$4,961,892.00
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9.20
52 Week Low
$0.26
$0.76
52 Week High
$2.33
$1.38

Technical Indicators

Market Signals
Indicator
CANF
PT
Relative Strength Index (RSI) 33.77 42.47
Support Level $0.26 $0.95
Resistance Level $0.30 $1.06
Average True Range (ATR) 0.03 0.06
MACD -0.00 -0.01
Stochastic Oscillator 8.75 3.19

Price Performance

Historical Comparison
CANF
PT

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About PT Pintec Technology Holdings Limited

Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.

Share on Social Networks: